Here's why ResMed shares can jump a further 20%

Investors have done very well from this stock recently. The good news is that analysts expect the trend to continue.

| More on:
Three excited business people cheer around a laptop in the office

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

ResMed Inc (ASX: RMD) shares are pushing higher on Monday.

In afternoon trade, the sleep disorder treatment company's shares are up 1% to $28.28.

This means that its shares are now up 33% since hitting a 52-week low in September.

Can ResMed shares keep rising?

While it might look like you're too late to the party, a number of analysts and fund managers don't believe that is the case.

For example, the team at Blackwattle highlighted ResMed shares as a key reason for the recent outperformance of the investment company's mid cap fund. It said:

Resmed rose 15% in January and was a key positive contributor to performance during the month. The company reported strong Dec Q results during the month which reinforced the company's ability to grow earnings with reasonable consistency in the face of the broadening GLP-1 class of drugs.

The fund manager also notes that concerns over weight loss drugs (GLP-1s) are unwarranted. So, with its shares still down 10% on a 12-month basis, Blackwattle appears confident on its investment in the company. It adds:

RMD also showed data that demonstrates patients who use both GLP-1 and CPAP treatment tend to benefit from therapy in combination, not in competition as the market assumed initially. RMD key competitor in CPAP, Philips (PHG EU), also continues to struggle with the repercussions of its highly damaging US recall, supporting our view that RMD will maintain higher market share levels the US.

Who else likes ResMed?

Blackwattle isn't alone with its positive view on ResMed. A number of brokers still see plenty of upside ahead for its shares. This includes Citi and Macquarie, which have the equivalent of buy ratings and price targets of $34.00 and $33.45, respectively.

This implies potential upside of 20% and 18% for investors over the next 12 months.

Citigroup is an advertising partner of The Ascent, a Motley Fool company. Motley Fool contributor James Mickleboro has positions in ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group and ResMed. The Motley Fool Australia has positions in and has recommended Macquarie Group and ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Bored man sitting at his desk with his laptop.
Healthcare Shares

The Cochlear share price hit a 52-week low last week, is it time to buy?

Is this an opportunity worth hearing about?

Read more »

A businesswoman exhales a deep sigh after receiving bad news, and gets on with it.
Earnings Results

Cochlear share price sinks 10% on half-year result disappointment

Let's see why investors are hitting the sell button this morning.

Read more »

Woman flexes muscles after donating blood.
Healthcare Shares

The CSL share price hit a 52-week low this week. Is it time to buy?

Is this beaten-up biotech a healthy opportunity?

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Sigma share price up 9% on first day of trading post-merger with Chemist Warehouse

It's a post-merger party for Sigma Healthcare shareholders today.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Up 135% in a year, why this ASX 200 healthcare stock is 'on track to become a truly great Australian success'

A leading fund manager expects more strong performance from this surging ASX 200 healthcare stock.

Read more »

Stethoscope with a piggy bank in the middle.
Healthcare Shares

With revenue up 9%, why does the NIB share price keep falling?

Will the ailing share price make a full recovery?

Read more »

Six smiling health workers pose for a selfie.
Healthcare Shares

Guess how much $5,000 invested in Sigma shares in December 2023 is worth now!

Sigma shares have soared over the past year alongside the merger with Chemist Warehouse.

Read more »

Woman with headphones on relaxing and looking at her phone happily.
Healthcare Shares

Everything you need to know about the latest CSL dividend

CSL's latest dividend should be turning investors' heads...

Read more »